



Not all **ADTs** for prostate cancer are the same^{1,2}

- FIRMAGON[®] is the **only GnRH antagonist available in Australia** for the treatment of prostate cancer³
- FIRMAGON[®] is the **only ADT that reduces testosterone levels to ≤ 0.5 ng/mL** after the first 3 days on treatment^{*1,2}

** Percentage of patients attaining $T \leq 0.5$ ng/mL by day 3 of treatment with FIRMAGON 240/80 mg s.c. = 96% and with Leuprorelin 7.5 mg i.m. = 0%¹*



PBS Information: Restricted benefit. Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.

Please review Product Information before prescribing. Product Information is available at www.ferring.com.au/products.html

Minimum Product Information: FIRMAGON[®] degarelix (as acetate). Powder and solvent for injection, depot, 120 and 80mg. **INDICATIONS:** Treatment of prostate cancer where androgen deprivation is warranted. **DOSAGE AND ADMINISTRATION:** Start with 240mg s.c. (two 120mg injections at a concentration of 40mg/mL), followed by monthly maintenance dose of 80mg s.c. (one injection at a concentration of 20mg/mL). Vary injection site. Do not rub or massage injection site. **CONTRAINDICATIONS:** Hypersensitivity to degarelix, excipients or any other GnRH antagonists. Women and children. **PRECAUTIONS:** QT prolongation; hypersensitivity; changes in bone density; changes in hepatic enzyme measurements; route of administration – do not give IV; severe renal or hepatic impairment; use only as first line ADT. **ADVERSE EFFECTS:** hot flushes; weight increase; injection site adverse events; liver transaminases increase; weight increase; hypertension; back pain; chills; arthralgia; urinary tract infection; constipation and fatigue. Please review full Product Information before prescribing – PI available from Ferring Pharmaceuticals. #27110-v3.

References: 1. Klotz L et al. BJU Int 2008; 102:1531-1538. 2. FIRMAGON[®] Product Information. 3. The Pharmaceutical Benefits Scheme (PBS) Website <https://www.pbs.gov.au/medicine/item/2784m-2785n> [Accessed 15 March 2022].

Cipla Australia Pty. Ltd., 132 Albert Road, South Melbourne, VIC 3205 Ph: +61 3 9696 4438
For medical enquiries, please contact Cipla Medical Information at 1800 875 117 or au.medinfo@cipla.com
FIRMAGON[®] is a registered trademark of Ferring B.V. Date prepared: October 2022

